What we know so far.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

What we know so far.

AIDS. 1996 Nov;10 Suppl 1:S3-7. Unique Identifier : AIDSLINE MED/97125597
Gazzard B; Chelsea and Westminster Hospital, London, UK.

Abstract: AIM: To review current knowledge of anti-HIV therapy and the implications for patient management. WHAT IS KNOWN: In three large clinical studies, combination therapy with zidovudine plus didanosine or zalcitabine improved survival and delayed clinical events in comparison with zidovudine alone, with greater benefits in zidovudine-naive than zidovudine-experienced patients. Initial studies suggest addition of an HIV protease inhibitor to combination therapy with two nucleoside analogues may result in greater reduction in viral loads, raising hopes about eradication therapy. Two clinical endpoint studies involving protease inhibitors are available. In one of these, saquinavir/zalcitabine combination therapy offered significant clinical benefits over monotherapy with either drug and in the other ritonavir improved survival in individuals with late HIV infection. IMPLICATIONS AND REMAINING QUESTIONS: It remains unclear at what stage therapy should be started. Evidence from clinical studies suggests initial therapy should be a combination regimen, probably two nucleoside inhibitors. Data from surrogate marker studies suggest that even greater reductions in viral load and increments in CD4+ count can be seen using triple therapy, either with two nucleosides and a non-nucleoside reverse transcriptase inhibitor, or two nucleoside analogues and a protease inhibitor. It remains unclear whether there is a qualitative difference between reducing viral load below detectable levels and more modest reductions in viral load, and whether immune destruction caused by HIV can be reversed and if sustained suppression of HIV replication can be achieved. CONCLUSIONS: It is now possible to offer real hope of improvements in survival to HIV-infected patients, through the use of combinations of antiretroviral agents, but more evidence from ongoing and further studies is still needed.

Keywords: *Anti-HIV Agents/THERAPEUTIC USE *HIV Infections/DRUG THERAPY
970630
M9761249

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .